Search

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

When Passion Starts as a Family Value and Continues as a Work Value

Discover who inspires members of our LatinX Business Resource Group.

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

Helping a Local Community in a Time of Need

Scleroderma

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Onboarding

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

World Water Day 2019 | Boehringer Ingelheim US

Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.

Boehringer Ingelheim Subsidiaries and Affiliate Companies

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease

BI Cares Financial Contributions Program

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

Women Inspiring Women: 5 questions for 6 women

Thinking differently could eradicate some areas of retinal disease

Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers